- Professor Keith Martin – Managing Director
- Associate Professor Peter van Wijngaarden – Deputy Director
- Professor Robyn Guymer – Deputy Director
- Leah Borsboom – Chief Operating Officer
- Professor Darren Kelly – Director of Enterprise and Innovation
- Sarah Rainbird – Head of Philanthropy and Fundraising
Professor Keith Martin
Keith Martin is Managing Director of CERA and Ringland Anderson Professor and Head of Ophthalmology at the University of Melbourne.
Until January 2019, he was Head of Ophthalmology at the University of Cambridge, Deputy Director of the University’s John van Geest Centre for Brain Repair and an Affiliate Principal Investigator at the Wellcome Trust – MRC Cambridge Stem Cell Institute. He was also Academic Lead for Ophthalmology and Lead Clinician for Glaucoma at the Cambridge University Hospitals NHS Foundation Trust.
He graduated from the University of Cambridge with a ‘Triple First’ in Medical Sciences and Neuroscience before completing clinical Training at Oxford University Clinical School, Ophthalmology Residency in Cambridge and Clinical and Research Fellowships in Glaucoma at Moorfields Eye Hospital in London and the Wilmer Eye Institute in Baltimore.
Professor Martin is working to develop new treatments for eye disease using stem cells, gene therapy and other techniques. In 2010, Professor Martin won the ARVO Foundation for Eye Research Translational Research Award, an international prize to a researcher from any country under the age of 50 years whose research is judged to have the potential to lead to major breakthroughs in the treatment of eye disease. He was also a winner of the World Glaucoma Association Senior Clinician Scientist Award in 2011 and was awarded the Duke Elder Medal by the Royal College of Ophthalmologists in 2017.
He is co-founder of Quethera, a Cambridge-based gene therapy company which has developed a gene therapy for glaucoma that is currently progressing towards human clinical trials. His other current main research interest is in the potential for regeneration and repair of nerve damage in the eye and brain.
Clinically, Professor Martin specialises in the medical and surgical management of complex glaucoma. He is currently President of the World Glaucoma Association, the largest glaucoma organisation in the world.
Associate Professor Peter van Wijngaarden
Associate Professor Peter van Wijngaarden is a Principal Investigator at CERA and a consultant ophthalmologist in the medical retina clinic at the Royal Victorian Eye and Ear Hospital. He has been a Deputy Director at CERA since 2017.
Read more about Peter on the Principal Investigators page.
Professor Robyn Guymer
Robyn Guymer is Professor of Ophthalmology at Melbourne University and a Deputy Director of CERA. She is also a senior retinal specialist at the Royal Victorian Eye and Ear Hospital. She is a clinician-scientist who leads a team of 20 researchers primarily investigating age-related macular degeneration (AMD).
Read more about Robyn on the Principal Investigators page.
Chief Operating Officer
Leah is a senior HR leader and consultant with close to 15 years of experience in generalist and specialist roles across the corporate, not-for-profit and justice sectors. She specialises in employee relations, workforce planning, remuneration, change management and leadership development.
Leah’s previous roles include working as a corporate lawyer and later, in a human resources management role, at Minter Ellison, and as the Resourcing & Remuneration Manager at Victoria Legal Aid.
In January 2018 she joined the Centre for Eye Research Australia as Head of People Development before moving into the Chief Operating Officer position. This diverse executive role involves managing the research support areas including human resource, legal, finance, communications, information technology, administration and facilities, as well as working closely with the Board and Executive to ensure good governance and operational implementation of CERA’s strategy.
Leah holds a Bachelor of Law (Hons) and is currently completing the Australian Institute of Company Directors course.
Professor Darren Kelly
Director of Enterprise and Innovation
Professor Darren Kelly is the Director of Enterprise and Innovation at CERA, the Associate Dean (Innovation and Enterprise, Medicine Dentistry Health Sciences) and the Director of Biomedical Research, Department of Medicine, University of Melbourne. He is the CEO of Certa Therapeutics and OccuRx, and Venture Partner (Entrepreneur in Residence) at Brandon Capital.
Head of Philanthropy and Fundraising
Sarah is a senior management professional with over 22 years of experience, including fundraising, business development and stakeholder relationship management, teaching, research, project management and corporate law.
Sarah began her career as a corporate lawyer in London and Melbourne at leading international law firms Clifford Chance, Ashurst, and Herbert Smith Freehills. From 2008-2016 she worked at Monash University, first as an academic and researcher in the Faculty of Art, Design and Architecture, then moving into the Office of the Vice-Chancellor as Development Manager for the Monash Law Faculty.
Prior to her current role as the Head of Philanthropy and Fundraising at CERA, Sarah was the National Manager, Individual & Family Philanthropy at Save the Children Australia.
Finance and Risk Committee
The Finance and Risk Committee, which reports to the Board, reviews the financial planning and management of the company, financial reporting and statutory compliance obligations, and oversees risk management, investments and commercialisation activities.
Nominations and Appointments Committee
The Nominations and Appointments Committee, which reports to the Board, was established in 2011. Its role is to consider and advise on succession planning and new appointments to the Board, senior researchers and senior management staff.
The Constitution requires the Company to have a Research Committee (RC) of no less than five members whose appointments are subject to approval by the Australian Taxation Office for the Company to maintain its status as an Approved Research Institute. The RC reports to the Board and has its own Charter.